Diagnostics
Ariba & Mac provides pharmaceutical Quality Assurance consulting for organizations that need to build, remediate or operate practical quality systems across GMP, GLP, GDP and GCP environments. Services can cover QMS design, audits, supplier qualification, deviations, CAPA, change control, documentation, training and inspection readiness.
Quality problems often become visible only when an inspection, client audit, batch issue or vendor failure exposes them. Common underlying causes include unclear ownership, inconsistent SOPs, weak deviation investigations, overdue CAPA, poor data-integrity controls or a quality system that exists on paper but is not embedded in daily operations. Our approach focuses on closing those operational gaps, not simply producing documents.
For pharmaceutical and life-sciences operations in Saudi Arabia, quality systems should be built around the applicable SFDA requirements and the relevant international GxP framework for the activity. We help teams translate those expectations into controlled procedures, records, training and evidence that can be demonstrated during audit or inspection.
GMP Quality Assurance Consulting: QMS, Audit & Inspection Readiness
The objective is a quality system that is proportionate to the operation, understood by the people using it, and able to produce traceable evidence of control when regulators, clients or partners review it.
- Contract or managed quality leadership to establish priorities, governance, management review and day-to-day QA oversight.
- Internal, vendor and for-cause GMP audits with documented observations, risk ranking and corrective-action follow-up.
- Inspection-readiness gap assessments, mock inspections, document-room preparation and role-based team coaching, supported by targeted GMP training where a competence gap is identified.
- QMS design or remediation covering SOPs, training, deviations, CAPA, change control, complaints and document control as applicable.
- Quality-risk management and data-integrity controls, including ALCOA+ principles and investigation practices.
- Supplier and service-provider qualification, technical/quality agreements, scorecards and periodic performance review for laboratories, manufacturers and CDMO/CMC partners.
- Quality KPIs, CAPA effectiveness checks and management-review inputs to support sustained compliance after the initial project.
QMS Design & Remediation
Build a lean, usable system around the actual process flow, responsibilities and risks rather than copying generic SOPs that staff cannot operate consistently.
Audits & Supplier Qualification
Identify quality and compliance risk in internal operations and outsourced partners, then track corrective actions to closure with evidence of effectiveness.
Inspection Readiness & Quality Leadership
Prepare documents, people and governance for regulator or client review while strengthening the day-to-day quality behaviors that inspections are designed to test.
Pharmaceutical QA Process: Gap Assessment, CAPA & Sustainable Compliance
We prioritize the gaps most likely to affect product quality, data integrity, patient safety or inspection outcomes, then implement corrective systems and verify that the controls are actually working.
- Map processes and responsibilities against the applicable GxP requirements, quality risks and current evidence rather than judging compliance from SOP titles alone.
- Use training, CAPA effectiveness, audit follow-up and management review to verify that remediation remains embedded after the project team steps back.
1. Assess, Risk-Rank & Remediate
Review the QMS, records, facilities and operating practices; identify critical and systemic gaps; then build a prioritized remediation plan with owners, evidence and realistic completion criteria.
2. Implement, Train & Verify
Deploy or revise procedures, train relevant roles, test the system through records and mock scenarios, and verify CAPA or process effectiveness before inspection or ongoing handover.
Quality Assurance for Growth, Outsourcing & Regulatory Inspection
A strong quality system has to work across departments and external partners. We connect quality requirements to operational reality so controls remain usable during scale-up, vendor changes, audits and regulatory interactions.
Risk-Based, Not Document-Heavy
Controls are prioritized according to product, process and compliance risk so the QMS supports the operation rather than creating unnecessary administrative load.
Cross-Functional Quality Ownership
Operations, laboratories, clinical teams, engineering and management are brought into the quality process so issues are not treated as the QA department’s responsibility alone.
Inspection-Ready Evidence
Training records, investigations, CAPA, change controls, qualification and audit evidence are organized so the team can explain both the procedure and how it is implemented in practice.
GMP Compliance Requires Evidence in Daily Operations
We distinguish between writing a procedure and proving that the procedure works. Recommendations are tied to the applicable operation, evidence and risk. No consultancy can guarantee a regulator’s inspection outcome, so readiness work is focused on reducing preventable gaps and improving the team’s ability to demonstrate control.
Authoritative Regulatory, Government & Academic Resources
For current official requirements, standards and sector guidance, consult the relevant authority directly. These independent external resources are provided for reference and do not imply affiliation or replace project-specific regulatory, legal or clinical advice.
- SFDA Good Manufacturing Practice (GMP) Guidelines — Official Saudi GMP guidance for regulated pharmaceutical manufacturing.
- ICH Quality Guidelines — International harmonized quality guidance including quality risk management and pharmaceutical quality systems.
- SFDA Laws and Regulations — Official Saudi regulatory repository for current laws, requirements and procedural rules.
FAQs About GMP & Quality Assurance Consulting in Saudi Arabia
Scope can include QMS design or remediation, SOPs, audits, supplier qualification, deviations, CAPA, change control, document control, training, data integrity, management review and inspection readiness.
We can perform a gap assessment, prioritize remediation, review the supporting evidence, run mock-inspection scenarios and coach teams on how to explain their processes and records. Final inspection outcomes remain with the relevant authority.
Yes. Audits can cover manufacturers, laboratories, packagers, suppliers and other GxP service providers, with observations, risk ranking, corrective-action expectations and follow-up.
We review event classification, investigation quality, root-cause methods, risk assessment, action ownership, due dates and effectiveness checks, then align procedures and training to the recurring weaknesses found.
Yes. The system is designed around the organization’s activity, lifecycle stage, regulatory scope and risk profile, with practical workflows and records that teams can sustain.
An organization chart, quality manual or core SOP list, recent audit or inspection observations, CAPA/deviation trends, product or service scope, key vendors and the next regulatory or client milestone provide a useful starting point.